Profil
John Fry worked at Alios BioPharma, Inc. from 2011 to 2018, where he held the position of VP-Head-Early Development & Infectious Diseases from 2014 to 2018.
He then joined Aligos Therapeutics, Inc. in 2018 and worked there until 2023 as the Executive Vice President-Clinical Development.
Prior to his professional career, Mr. Fry completed his undergraduate degree at the University of Sussex.
Ehemalige bekannte Positionen von John Fry
| Unternehmen | Position | Ende |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2023 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2014 |
Ausbildung von John Fry
| University of Sussex | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
